MGTA - マジェンタ・セラピュ―ティクス (Magenta Therapeutics Inc.) マジェンタ・セラピュ―ティクス



symbol MGTA
会社名 Magenta Therapeutics Inc (マジェンタ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Magenta Therapeutics Inc. is a clinical-stage biotechnology company. The Company is developing therapeutics to transform hematopoietic stem cell transplants for patients with immune and blood-based diseases. It maintains a platform with integrated and modular approach which aims to reboot the blood and immune systems. The Company’s products include MGTA-145 MGTA-456 E478 and G100. The Company also developing a pipeline of small molecules; biologics including antibody drug conjugates; and a cell therapy which transplant options for many more patients with autoimmune diseases blood cancers and genetic diseases. The Company’s C100 program targets HSCs immune cells and disease-causing cells the C200 program targets HSCs and disease-causing cells and the C300 program targets only immune cells. This is achieved by tuning the antibodies to specific cellular markers or receptors that are expressed on the particular cell types.   マジェンタ・セラピュ―ティクスは米国のバイオ医薬品企業。臨床段階で、自己免疫疾患、血液のがん、希少遺伝病を治療する骨髄移植においてニ―ズの満たされていない分野における治療法の開発に従事する。同社は多発性硬化症、強皮症、急性骨髄性白血病、骨髄異形成症候群、遺伝性代謝疾患の治療に取り組む。本社所在地はマサチュ―セッツ州ケンブリッジ。   Magenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers platform that focuses on critical areas of transplant medicine. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner in June 2015 and is headquartered in Cambridge, MA.
本社所在地 50 Hampshire Street Cambridge MA 02139 USA
代表者氏名 Michael W. Bonney マイケル・W・ボニー
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 857-201-2700
設立年月日 42156
市場名 NASDAQ National Market System
ipoyear 2018年
終値(lastsale) 10.5
時価総額(marketcap) 345919717.5
時価総額 時価総額(百万ドル) 331.75350
売上高 売上高(百万ドル) --
企業価値(EV) 企業価値(EV)(百万ドル) 158.32450
当期純利益 当期純利益(百万ドル) --
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Magenta Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders totaled to $24.9M.



   Magenta Therapeutics Sees Hammer Chart Pattern: Time to Buy?  2019/10/09 12:14:00 Zacks Investment Research
Magenta Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
   Magenta Therapeutics: Targeted Conditioning Agents Drive Long-Term Upside  2019/05/29 21:37:20 Seeking Alpha
   Biotech News Recap: Key NASH Readout Coming Up For CymaBay Therapeutics  2019/05/09 23:44:35 Seeking Alpha
   Magenta Therapeutics beats by $0.13  2019/05/09 12:20:57 Seeking Alpha
   Magenta prices equity offering; shares down 2% premarket  2019/05/02 11:06:26 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 マジェンタ・セラピュ―ティクス MGTA Magenta Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)